Results 61 to 70 of about 10,061 (158)

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
Incorporation of clinical, demographic, and CYP2C19 genetic information from a large clinical trial dataset of post‐PCI patients into a machine learning model and validated with a real‐world registry aids prediction of ischemic events at 1 year. The model can help safely de‐escalate DAPT to individualize and balance competing ischemic and bleeding ...
Caroline W. Grant, Brenden S. Ingraham, Ryan J. Lennon, Anvi Raina, Shulan Tian, Gurukripa Kowlgi, Larisa H. Cavallari, Craig R. Lee, Amber Beitelshees, Dominick J. Angiolillo, Francesco Franchi, Julio D. Duarte, Joseph S. Rossi, George A. Stouffer, Eric Klee, Rajiv Gulati, Charanjit Rihal, Michael Farkouh, Arjun P. Athreya, Naveen L. Pereira   +19 more
wiley   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5614-5626, July 2026.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Early Mobilization After Pacemaker Implantation

Pacing and Clinical Electrophysiology, Volume 49, Issue 7, Page 962-967, July 2026.
ABSTRACT Background The increasing use of cardiac implantable electronic devices (CIED) is leading to a rise in procedure‐related complications. Objective This trial aimed to assess the safety and feasibility of early mobilization and the possibility of same‐day discharge following permanent pacemaker implantation.
Jiří Šmíd, Vlastimil Vančura, Martin Brada, Richard Rokyta   +3 more
wiley   +1 more source

Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels

Cardiovascular Diabetology, 2020
Background Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional readout and biomarker kinetics in
William A. E. Parker, Christian Schulte, Temo Barwari, Fladia Phoenix, Sam M. Pearson, Manuel Mayr, Peter J. Grant, Robert F. Storey, Ramzi A. Ajjan   +8 more
doaj   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

Catheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2293-2303, June 1, 2026.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu, Antonin Trimaille, Amandine Granier, Adrien Carmona, Anis Elidrissi, Marion Kibler, Laurence Jesel, Patrick Ohlmann, Laurent Sattler, Olivier Morel   +9 more
wiley   +1 more source

Absence of differential effect of ticagrelor versus prasugrel maintenance dose on endothelial function in patients with stable coronary artery disease

Hellenic Journal of Cardiology, 2018
Background: Endothelial function may be improved by ticagrelor through adenosine-mediated mechanisms. We aimed to assess the effect of ticagrelor versus prasugrel on endothelial function in patients with stable coronary artery disease (CAD).
Ioanna Xanthopoulou, Ilianna Bei, Theodora Bampouri, Nikolaos Barampoutis, Athanasios Moulias, Periklis Davlouros, Dimitrios Alexopoulos   +6 more
doaj   +1 more source

Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 6, June 2026.
ABSTRACT Background High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its ...
Emad Uddin Sajid, Muhammad Hasnain Azeem, Alishba Fatima, Syeda Masooma Jafri, Danish Hassan, Taha Ibrahim, Kashish Zehra Manjee, Syed Rayyan Ahmed, Tooba Ali, Rida Shakeel, Muhammad Usman, Raghabendra Kumar Mahato, Danish Bawa   +12 more
wiley   +1 more source

The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials

BMC Cardiovascular Disorders, 2020
Background Ticagrelor and prasugrel are two third-generation oral P2Y12 inhibitors which are more commonly used in clinical practice. However, dyspnea has been consecutively reported in patients using third-generation oral P2Y12 inhibitors.
Na Zhang, Weisen Xu, Ou Li, Bing Zhang
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)

Российский кардиологический журнал, 2019
The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled
S. N. Tereshchenko, M. G. Glezer, S. A. Abugov, O. V. Averkov, S. I. Antipov, A. S. Galyavich, M. Yu. Gilyarov, D. V. Duplyakov, A. A. Efremushkina, D. A. Zateyshchikov, V. V. Ivanenko, E. D. Kosmacheva, O. V. Krestyaninov, Yu. M. Lopatin, E. P. Panchenko, V. V. Ryabov, E. V. Samokhvalov, I. I. Staroverov, S. A. Ustyugov, A. V. Khripun, S. V. Shalaev, R. M. Shakhnovich, I. S. Yavelov, A. N. Yakovlev, S. S. Yakushin   +24 more
doaj   +1 more source